166 related articles for article (PubMed ID: 23731573)
1. N-acetylcysteine does not prevent contrast nephropathy in patients with renal impairment undergoing emergency CT: a randomized study.
Poletti PA; Platon A; De Seigneux S; Dupuis-Lozeron E; Sarasin F; Becker CD; Perneger T; Saudan P; Martin PY
BMC Nephrol; 2013 Jun; 14():119. PubMed ID: 23731573
[TBL] [Abstract][Full Text] [Related]
2. I.v. N-acetylcysteine and emergency CT: use of serum creatinine and cystatin C as markers of radiocontrast nephrotoxicity.
Poletti PA; Saudan P; Platon A; Mermillod B; Sautter AM; Vermeulen B; Sarasin FP; Becker CD; Martin PY
AJR Am J Roentgenol; 2007 Sep; 189(3):687-92. PubMed ID: 17715118
[TBL] [Abstract][Full Text] [Related]
3. Prevention of contrast-induced nephropathy in vascular patients undergoing angiography: a randomized controlled trial of intravenous N-acetylcysteine.
Rashid ST; Salman M; Myint F; Baker DM; Agarwal S; Sweny P; Hamilton G
J Vasc Surg; 2004 Dec; 40(6):1136-41. PubMed ID: 15622367
[TBL] [Abstract][Full Text] [Related]
4. The impact of N-acetylcysteine and ascorbic acid in contrast-induced nephropathy in critical care patients: an open-label randomized controlled study.
Palli E; Makris D; Papanikolaou J; Garoufalis G; Tsilioni I; Zygoulis P; Zakynthinos E
Crit Care; 2017 Oct; 21(1):269. PubMed ID: 29089038
[TBL] [Abstract][Full Text] [Related]
5. Usefulness of N-acetylcysteine or ascorbic acid versus placebo to prevent contrast-induced acute kidney injury in patients undergoing elective cardiac catheterization: a single-center, prospective, randomized, double-blind, placebo-controlled trial.
Brueck M; Cengiz H; Hoeltgen R; Wieczorek M; Boedeker RH; Scheibelhut C; Boening A
J Invasive Cardiol; 2013 Jun; 25(6):276-83. PubMed ID: 23735352
[TBL] [Abstract][Full Text] [Related]
6. Effect of hydration with or without n-acetylcysteine on contrast induced nephropathy in patients undergoing coronary angiography and percutaneous coronary intervention.
Awal A; Ahsan SA; Siddique MA; Banerjee S; Hasan MI; Zaman SM; Arzu J; Subedi B
Mymensingh Med J; 2011 Apr; 20(2):264-9. PubMed ID: 21522098
[TBL] [Abstract][Full Text] [Related]
7. N-acetylcysteine plus intravenous fluids versus intravenous fluids alone to prevent contrast-induced nephropathy in emergency computed tomography.
Traub SJ; Mitchell AM; Jones AE; Tang A; O'Connor J; Nelson T; Kellum J; Shapiro NI
Ann Emerg Med; 2013 Nov; 62(5):511-520.e25. PubMed ID: 23769807
[TBL] [Abstract][Full Text] [Related]
8. Do intravenous N-acetylcysteine and sodium bicarbonate prevent high osmolal contrast-induced acute kidney injury? A randomized controlled trial.
Inda-Filho AJ; Caixeta A; Manggini M; Schor N
PLoS One; 2014; 9(9):e107602. PubMed ID: 25254489
[TBL] [Abstract][Full Text] [Related]
9. Oral acetylcysteine does not protect renal function from moderate to high doses of intravenous radiographic contrast.
Boccalandro F; Amhad M; Smalling RW; Sdringola S
Catheter Cardiovasc Interv; 2003 Mar; 58(3):336-41. PubMed ID: 12594698
[TBL] [Abstract][Full Text] [Related]
10. Prevention of acute renal failure post-contrast imaging in cardiology: a randomized study.
Alessandri N; Lanzi L; Garante CM; Tersigni F; Sergiacomi R; Petrassi M; Di Matteo A; Tufano F
Eur Rev Med Pharmacol Sci; 2013 Feb; 17 Suppl 1():13-21. PubMed ID: 23436661
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of vitamin E and N-acetylcysteine in the prevention of contrast induced kidney injury in patients with chronic kidney disease: a double blind, randomized controlled trial.
Kitzler TM; Jaberi A; Sendlhofer G; Rehak P; Binder C; Petnehazy E; Stacher R; Kotanko P
Wien Klin Wochenschr; 2012 May; 124(9-10):312-9. PubMed ID: 22527829
[TBL] [Abstract][Full Text] [Related]
12. The effectiveness of N-Acetylcysteine in preventing contrast-induced nephropathy in patients undergoing contrast-enhanced computed tomography: a meta-analysis of randomized controlled trials.
Wu MY; Hsiang HF; Wong CS; Yao MS; Li YW; Hsiang CY; Bai CH; Hsu YH; Lin YF; Tam KW
Int Urol Nephrol; 2013 Oct; 45(5):1309-18. PubMed ID: 23283594
[TBL] [Abstract][Full Text] [Related]
13. Renal Insufficiency After Contrast Media Administration Trial II (REMEDIAL II): RenalGuard System in high-risk patients for contrast-induced acute kidney injury.
Briguori C; Visconti G; Focaccio A; Airoldi F; Valgimigli M; Sangiorgi GM; Golia B; Ricciardelli B; Condorelli G;
Circulation; 2011 Sep; 124(11):1260-9. PubMed ID: 21844075
[TBL] [Abstract][Full Text] [Related]
14. Impact of high-dose N-acetylcysteine versus placebo on contrast-induced nephropathy and myocardial reperfusion injury in unselected patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention. The LIPSIA-N-ACC (Prospective, Single-Blind, Placebo-Controlled, Randomized Leipzig Immediate PercutaneouS Coronary Intervention Acute Myocardial Infarction N-ACC) Trial.
Thiele H; Hildebrand L; Schirdewahn C; Eitel I; Adams V; Fuernau G; Erbs S; Linke A; Diederich KW; Nowak M; Desch S; Gutberlet M; Schuler G
J Am Coll Cardiol; 2010 May; 55(20):2201-9. PubMed ID: 20466200
[TBL] [Abstract][Full Text] [Related]
15. Comparison of short-term infusion regimens of N-acetylcysteine plus intravenous fluids, sodium bicarbonate plus intravenous fluids, and intravenous fluids alone for prevention of contrast-induced nephropathy in the emergency department.
Kama A; Yılmaz S; Yaka E; Dervişoğlu E; Doğan NÖ; Erimşah E; Pekdemir M
Acad Emerg Med; 2014 Jun; 21(6):615-22. PubMed ID: 25039544
[TBL] [Abstract][Full Text] [Related]
16. Does intravenous or oral high-dose N-acetylcysteine in addition to saline prevent contrast-induced nephropathy assessed by cystatin C?
Erturk M; Uslu N; Gorgulu S; Akbay E; Kurtulus G; Akturk IF; Akgul O; Surgit O; Uzun F; Gul M; Isiksacan N; Yildirim A
Coron Artery Dis; 2014 Mar; 25(2):111-7. PubMed ID: 24365793
[TBL] [Abstract][Full Text] [Related]
17. Comparison of combination therapy of high-dose oral N-acetylcysteine and intravenous sodium bicarbonate hydration with individual therapies in the reduction of Contrast-induced Nephropathy during Cardiac Catheterisation and Percutaneous Coronary Intervention (CONTRAST): A multi-centre, randomised, controlled trial.
Chong E; Poh KK; Lu Q; Zhang JJ; Tan N; Hou XM; Ong HY; Azan A; Chen SL; Chen JY; Ali RM; Fang WY; Lau TW; Tan HC
Int J Cardiol; 2015 Dec; 201():237-42. PubMed ID: 26301645
[TBL] [Abstract][Full Text] [Related]
18. Effect of N-acetylcysteine for prevention of contrast nephropathy in patients with moderate to severe renal insufficiency: a randomized trial.
Fung JW; Szeto CC; Chan WW; Kum LC; Chan AK; Wong JT; Wu EB; Yip GW; Chan JY; Yu CM; Woo KS; Sanderson JE
Am J Kidney Dis; 2004 May; 43(5):801-8. PubMed ID: 15112170
[TBL] [Abstract][Full Text] [Related]
19. Prevention of radiocontrast-induced nephropathy with N-acetylcysteine in patients undergoing coronary angiography.
Tadros GM; Mouhayar EN; Akinwande AO; Campbell B; Wood C; Blankenship JA
J Invasive Cardiol; 2003 Jun; 15(6):311-4. PubMed ID: 12777667
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of ascorbic acid, N-acetylcysteine, or combination of both on top of saline hydration versus saline hydration alone on prevention of contrast-Induced nephropathy: a prospective randomized study.
Albabtain MA; Almasood A; Alshurafah H; Alamri H; Tamim H
J Interv Cardiol; 2013 Feb; 26(1):90-6. PubMed ID: 22994682
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
